Short-read Sequencing Market by Product, Technology, Read Type, Throughput, Data Output, Application

List of Tables

The Short-read Sequencing Market is projected to grow by USD 22.76 billion at a CAGR of 16.42% by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 7.84 billion
Estimated Year [2026]	USD 9.15 billion
Forecast Year [2032]	USD 22.76 billion
CAGR (%)	16.42%

Short-Read Sequencing Platform Outlook

Short-read sequencing remains the workhorse of next-generation sequencing because it delivers high-throughput, accurate reads for whole-genome sequencing, exome sequencing, RNA sequencing, metagenomics, single-cell assays, and targeted panels.

For platform, reagent, and consumables suppliers, demand is anchored in clinical genomics, oncology, inherited disease testing, infectious disease surveillance, agricultural genomics, and biopharma research, where reproducible chemistry, automation, quality controls, and validated workflows are essential purchasing criteria.

Transformative Shifts in Short-Read Sequencing

The short-read sequencing landscape is shifting from centralized, research-only sequencing toward distributed, regulated, and application-specific workflows. Buyers increasingly evaluate total cost per sample, library preparation efficiency, turnaround time, sample throughput, informatics compatibility, and evidence of analytical validity.

Competition is also broadening as high-throughput instruments, benchtop systems, patterned flow cells, multiplexed workflows, and integrated sample-to-report models reduce access barriers while raising expectations for service continuity, uptime, data quality, and supply assurance.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming central to short-read sequencing workflows across base calling, variant calling, quality control, contamination detection, read alignment support, phenotype interpretation, and clinical report prioritization. Peer-reviewed benchmarking has shown that deep-learning variant callers can improve germline and somatic variant detection performance when paired with well-characterized datasets and validated pipelines.

For instrument and workflow leaders, AI shifts differentiation from hardware alone to combined chemistry, signal processing, cloud or on-premise bioinformatics, cybersecurity, auditability, and explainable analytics that can support regulated clinical, translational, and research use.

Key Regional Insights for Short-Read Sequencing

North America leads adoption through strong academic medical centers, commercial laboratories, public health sequencing networks, NIH-supported genomics initiatives, and FDA-recognized pathways for next-generation sequencing diagnostics. Europe benefits from national genomics programs, GDPR-governed data practices, biobank infrastructure, and expanding clinical sequencing under public health systems, while the European IVDR continues to influence validation, documentation, and post-market evidence expectations.

Asia-Pacific is scaling rapidly as China, Japan, South Korea, India, Australia, and ASEAN markets invest in precision medicine, pathogen surveillance, newborn and rare disease programs, cancer genomics, and population genomics. Latin America is showing rising demand led by Brazil and Mexico, where oncology diagnostics, infectious disease monitoring, and academic sequencing networks are expanding access. The Middle East is accelerating adoption through precision health strategies, national genome initiatives, and tertiary care investments, while Africa is strengthening sequencing capacity through infectious disease surveillance, antimicrobial resistance monitoring, and regional genomics training networks.

Key Group Insights Across Global Alliances

The G7 continues to shape clinical standards, reimbursement evidence, public health preparedness, and large-scale research funding for short-read sequencing, while the European Union influences compliance through GDPR, IVDR, health data governance, and cross-border research collaboration. NATO-aligned countries increasingly view genomic surveillance as part of biosecurity readiness, including pathogen monitoring, outbreak response, and resilient laboratory infrastructure.

BRICS nations are expanding domestic sequencing capacity, data sovereignty policies, biobank development, and population-scale research to reduce dependence on external infrastructure and strengthen local genomics ecosystems. ASEAN countries are investing in infectious disease genomics, cancer testing, and regional laboratory modernization, while GCC markets are advancing precision health, newborn screening, rare disease genomics, and national genome programs, creating demand for robust, scalable short-read sequencing platforms with local service, training, and informatics support.

Key Country Insights for Short-Read Sequencing

The United States remains a major innovation hub, supported by NIH funding, CLIA-certified laboratories, oncology testing, rare disease programs, biopharma demand, and public health sequencing capacity. Canada advances adoption through provincial healthcare systems, research hospitals, and national genomics funding, while Mexico is expanding access through academic centers, oncology demand, and infectious disease applications. Brazil leads Latin American sequencing activity through research institutes, public health surveillance, and cancer genomics initiatives.

In Europe, the United Kingdom, Germany, France, Italy, and Spain advance short-read sequencing through public health systems, national genomics strategies, cancer and rare disease programs, and biobank-linked research, while Russia maintains research and public health sequencing capacity shaped by domestic procurement and localization priorities. In Asia-Pacific, China, Japan, South Korea, India, and Australia are expanding population genomics, clinical testing, reproductive health applications, agricultural genomics, and pathogen surveillance, with Australia also supported by strong translational research networks and national precision medicine initiatives.

Actionable Recommendations for Industry Leaders

Industry leaders should align instrument roadmaps with validated clinical workflows, reduce cost per high-quality genome or panel, and strengthen library preparation automation, sample tracking, and contamination control. Partnerships with hospital systems, reference laboratories, academic medical centers, public health agencies, and biopharma teams can accelerate evidence generation and workflow adoption.

Suppliers should also invest in AI-enabled quality metrics, transparent variant calling performance, cybersecurity, interoperability with laboratory information systems, flexible deployment models, and regional service networks to reduce downtime and support regulated use across research, clinical, and public health environments.

Research Methodology

This executive summary is based on secondary research across peer-reviewed genomics literature, public health sequencing programs, regulatory guidance, clinical laboratory standards, institutional genomics initiatives, and recognized scientific sources.

Insights were triangulated by application area, region, customer type, technology adoption signals, workflow requirements, regulatory context, and public health use cases to identify evidence-backed trends shaping short-read sequencing demand and commercialization without relying on market sizing, market share, or forecasting assumptions.

Conclusion

Short-read sequencing continues to define scalable genomics because it combines throughput, accuracy, ecosystem maturity, validated workflows, and broad application coverage across clinical diagnostics, population genomics, oncology, infectious disease surveillance, and life science research.

The next phase of competition will depend on integrated platforms that combine sequencing chemistry, automation, AI analytics, regulatory readiness, data security, interoperability, and service reliability into dependable sample-to-insight workflows for laboratories worldwide.

Product Code: MRR-AD36CD898498

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Short-read Sequencing Market, by Product

7.1. Consumables
- 7.1.1. Flow Cells & Reagents
- 7.1.2. Library Prep Kits
7.2. Instruments
- 7.2.1. Benchtop Sequencers
- 7.2.2. High-Throughput Sequencers
7.3. Software & Services
- 7.3.1. Bioinformatics Services
- 7.3.2. Data Analysis Software

8. Short-read Sequencing Market, by Technology

8.1. Semiconductor Sequencing
- 8.1.1. Ion Proton
- 8.1.2. Ion Torrent PGM
8.2. Sequencing Ligation
8.3. Sequencing Synthesis

9. Short-read Sequencing Market, by Read Type

9.1. Single-End Reads
9.2. Paired-End Reads

10. Short-read Sequencing Market, by Throughput

10.1. Low
10.2. Medium
10.3. High

11. Short-read Sequencing Market, by Data Output

11.1. Alignment
11.2. De Novo Assembly
11.3. Variant Analysis

12. Short-read Sequencing Market, by Application

12.1. Epigenomics
- 12.1.1. Chromatin Accessibility Analysis
- 12.1.2. DNA Methylation Analysis
12.2. Genomics
- 12.2.1. Resequencing
- 12.2.2. Targeted Sequencing
- 12.2.3. Whole Genome Sequencing
12.3. Metagenomics
12.4. Transcriptomics

13. Short-read Sequencing Market, by Region

13.1. Asia-Pacific
13.2. North America
13.3. Latin America
13.4. Europe
13.5. Middle East
13.6. Africa

14. Short-read Sequencing Market, by Group

14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO

15. Short-read Sequencing Market, by Country

15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea

16. Competitive Landscape

16.1. Market Concentration Analysis, 2025
- 16.1.1. Concentration Ratio (CR)
- 16.1.2. Herfindahl Hirschman Index (HHI)
16.2. Recent Developments & Impact Analysis, 2025
16.3. Product Portfolio Analysis, 2025
16.4. Benchmarking Analysis, 2025

17. Company Profiles

17.1. Agilent Technologies, Inc.
17.2. BGI Genomics Co., Ltd.
17.3. Bio-Rad Laboratories, Inc.
17.4. Danaher Corporation
17.5. Eppendorf SE
17.6. Eurofins Scientific SE
17.7. F. Hoffmann-La Roche Ltd
17.8. GE HealthCare Technologies Inc.
17.9. Genewiz, Inc.
17.10. Hamilton Company
17.11. Illumina, Inc.
17.12. Macrogen, Inc.
17.13. Novogene Co., Ltd.
17.14. Oxford Nanopore Technologies plc
17.15. Pacific Biosciences of California, Inc.
17.16. PerkinElmer, Inc.
17.17. Psomagen, Inc.
17.18. Qiagen N.V.
17.19. Takara Bio Inc.
17.20. Thermo Fisher Scientific Inc.